Andere talen Paradigm Biopharmaceuticals Limited

Aandelen

PAR

AU000000PAR5

Vertraagde tijd Australian S.E. Andere beurzen 02:45:08 21-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,255 ^AUD	-1,92%		-12,50%	-42,35%

28/02	Paradigm Biopharmaceuticals Limited rapporteert resultaten voor het halfjaar dat eindigde op 31 december 2023	CI
12/02	Paradigm Biopharma's injecteerbare pentosan polysulfaatnatrium studie bereikt eindpunt	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program	19/04
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02
Paradigm Biopharma's Injectable Pentosan Polysulfate Sodium Trial Reaches Endpoint	12/02
Paradigm Biopharmaceuticals Secures AU$7 Million R&D Tax Incentive Rebate for Fiscal Year 2023; Shares Rally 9%	07/02
Paradigm Biopharmaceuticals Opens Retail Entitlement Offer	06/11
Paradigm Biopharmaceuticals Raising AU$30 Million for Clinical Trial	30-10-23
Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately	20-10-23
Paradigm Biopharmaceuticals Validates Cartilage Preservation in Knee Osteoarthritis Trial	18-10-23
Paradigm Biopharmaceuticals Confirms Effectivity of Pain Medication in Osteoarthritis Trial	10-10-23
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25-08-23
Paradigm Biopharmaceuticals Validates Efficacy of Anti-Inflammatory Medication in Canine Trial	02-06-23
Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up	11-04-23
Paradigm Biopharmaceuticals Announces Phase 2 Trial in Osteoarthritis Shows Signs of Disease Modification At 6-Month Follow-Up	11-04-23
Paradigm Biopharmaceuticals Limited Announces Injectable PPS Demonstrates Multiple Signals of A DMOAD in PARA_OA_008 Phase 2 Clinical Study	04-04-23
Paradigm Biopharmaceuticals Secures European Ethics Approval for Knee Osteoarthritis Trial	14-03-23
Paradigm Biopharmaceuticals Ltd Receives European Regulatory and Ethics Approval for the Pivotal PARA_OA_002 Global Clinical Trial	13-03-23
Starpharma Appoints CFO	03-03-23
Paradigm Biopharmaceuticals Names Interim CFO	03-03-23
Paradigm Biopharmaceuticals Limited Announces the Change of Chief Financial Officer	02-03-23
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022	26-02-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Paradigm Biopharmaceuticals Limited

Aandelen

PAR

AU000000PAR5

Andere talen

Filters